Recent Updates
Recently added Catalysts

CNTO 2476

Phase 1

Age-related Macular Degeneration | Monoclonal antibody | Ophthalmology |Johnson & Johnson|Last Updated: Aug 8, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment39
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01226628A Safety Study of CNTO 2476 in Patients With Age-Related Macular DegenerationPHASE1 COMPLETED 39Oct 21, 2010May 31, 2017Aug 8, 20172 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of eyes with serious ocular adverse events occurring over the first 12 months of the study
12 months

This number will be summarized descriptively for treated and fellow eyes within each dose level included in Phase 1 and Phase 2a portions of the study

Secondary Endpoints
Change from baseline in antibody peak values
Baseline (Screening), up to 60 months
Yearly rate of increase from baseline in area of Geographic Atrophy (GA)
Baseline (Screening), up to 60 months
Changes from baseline in visual function
Baseline (Screening), up to 60 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort AEXPERIMENTALPhase 1: 3 patients will receive 60,000 human umbilical tissue-derived cells (hUTC)
Cohort BEXPERIMENTALPhase 1: 3 patients will receive 120,000 hUTC
Cohort CEXPERIMENTALPhase 1: 3 patients will receive 300,000 hUTC
Cohort DEXPERIMENTALPhase 1: 3 patients will receive 560,000 hUTC
Cohort EEXPERIMENTALPhase 1: 6 patients will receive 300,000 hUTC
Cohort FEXPERIMENTALPhase 1: 6 patients will receive either 60,000 or 300,000 hUTC
Cohort GEXPERIMENTALPhase 1: 6 patients will receive either 60,000 or 300,000 hUTC
Phase 2aEXPERIMENTALUp to 38 patients will receive one of two optimal doses as selected from the Phase 1 portion of the study
Interventions
NameTypeDescription
CNTO 2476BIOLOGICAL -
iTrack Model 275 micro catheterPROCEDURECNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
Unlock Study Design Details
Eligibility Criteria
Age Range50 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Women must be incapable of childbearing * Patient must be a suitable candidate for ophthalmologic surgery, is willing and able to comply with the surgical procedure, scheduled visits, treatment plan, laboratory tests and other study procedures * Confirmed diagnosis of bilatera...

Countries:United States
Unlock Eligibility Criteria